Impact of the motor complications of Parkinson's disease on the quality of life

被引:415
作者
Chapuis, S [1 ]
Ouchchane, L
Metz, O
Gerbaud, L
Durif, F
机构
[1] Ctr Hosp Vichy, Serv Neurol, Vichy, France
[2] Serv Epidemiol & Econ Sante, Clermont Ferrand, France
[3] Ctr Hosp Univ, Serv Neurol A, Clermont Ferrand, France
关键词
Parkinson's disease; quality of life; motor complications;
D O I
10.1002/mds.20279
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The impact of motor complications of Parkinson's disease (PD), especially levodopa-induced dyskinesias, on quality of life (QL) was studied in 143 patients with PD. All were evaluated on the Hoehn and Yahr (H&Y) scale, and the Motor part of the Unified Parkinson's Disease Rating Scale (UPDRS). Motor complications were analyzed using the UPDRS Parts IVA and IVB and the Abnormal Involuntary Movement Scale. A specific Parkinson's disease quality of life questionnaire (39-item version, PDQ-39) was used. Motor complications significantly worsened the PDQ-39 Summary Index (PDQ-SI) of patients with PD. The dimensions of Mobility, Activities of Daily Living, Stigma, and Communication were the most strongly affected. "Peak dose" dyskinesia decreased Mobility, Emotional Well-Being, and Cognition, whereas biphasic dyskinesia affected Mobility, Stigma, Communication, and Activities of Daily Living. Morning akinesia, end-of-dose fluctuations, and "unpredictable offs" decreased QL on the dimensions of Mobility, Activities of Daily Living, Stigma, and Communication. Nocturnal akinesia, led to a deterioration of all dimensions of the PDQ-39. Thus, motor complications and especially nocturnal akinesia and biphasic dyskinesias worsened the QL of PD patients. (C) 2004 Movement Disorder Society.
引用
收藏
页码:224 / 230
页数:7
相关论文
共 40 条
  • [1] Auquier P, 2002, REV NEUROL-FRANCE, V158, P41
  • [2] THE SICKNESS IMPACT PROFILE - DEVELOPMENT AND FINAL REVISION OF A HEALTH-STATUS MEASURE
    BERGNER, M
    BOBBITT, RA
    CARTER, WB
    GILSON, BS
    [J]. MEDICAL CARE, 1981, 19 (08) : 787 - 805
  • [3] BLIN J, 1998, NEUROLOGY, V38, P140
  • [4] Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease - A multicenter 5-year study
    Block, G
    Liss, C
    Reines, S
    Irr, J
    Nibbelink, D
    Aarli, J
    Aguilar, M
    Ahrens, S
    Bakheit, A
    Baumel, B
    Bertoni, J
    Capildeo, R
    CastroCaldas, A
    Deza, L
    Donaldson, I
    Franck, G
    Fusillo, J
    Gauthier, S
    Gershanik, O
    Granerus, AK
    Hauser, RA
    Hennessey, K
    Hutton, JT
    Joffe, R
    Koller, W
    Last, B
    LeWitt, P
    Mamoli, B
    Manyam, B
    Mark, M
    Nakano, K
    Nausieda, P
    Otero, E
    Paulson, G
    Pinter, M
    Reich, S
    Rodnitzky, R
    Sage, J
    Sampaio, C
    Smith, B
    Teravainen, H
    Tetrud, J
    Tolosa, E
    Ulm, G
    Valesco, F
    [J]. EUROPEAN NEUROLOGY, 1997, 37 (01) : 23 - 27
  • [5] EuroQol: The current state of play
    Brooks, R
    [J]. HEALTH POLICY, 1996, 37 (01) : 53 - 72
  • [6] Calne S, 1996, Parkinsonism Relat Disord, V2, P55, DOI 10.1016/1353-8020(95)00026-7
  • [7] Clarke CE, 2002, NEUROLOGY, V58, pA469
  • [8] Evaluation of a measurement strategy for Parkinson's disease: Assessing patient health-related quality of life
    Damiano, AM
    McGrath, MM
    Willian, MK
    Snyder, CF
    LeWitt, PA
    Reyes, PF
    Richter, RR
    Means, ED
    [J]. QUALITY OF LIFE RESEARCH, 2000, 9 (01) : 87 - 100
  • [9] Quality of life in patients with Parkinson's disease: Development of a questionnaire
    deBoer, AGEM
    Wijker, W
    Speelman, JD
    deHaes, JCJM
    [J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1996, 61 (01) : 70 - 74
  • [10] Health-related quality of life and healthcare utilisation in patients with Parkinson's disease - Impact of motor fluctuations and dyskinesias
    Dodel, RC
    Berger, K
    Oertel, WH
    [J]. PHARMACOECONOMICS, 2001, 19 (10) : 1013 - 1038